Piramal Pharma

Indian benchmark indices, Sensex and Nifty 50, opened higher on July 6, driven by gains in private banking stocks following strong quarterly updates from HDFC Bank and Axis Bank. Market breadth was positive with 14 of the 16 major indices in the green.

The Indian stock market extended its losses on March 12, with the Nifty 50 and Sensex down 1% and 1.08%. Tensions in the Middle East affected investor sentiment, particularly impacting auto stocks, while broader markets showed some positive movement.

Buy or sell stocks: Vaishali Parekh recommends three stocks to buy today — Piramal Pharma, Bharat Dynamics, and Oberoi Realty

Piramal Pharma's plea is slated to be heard on 9 February before a bench led by Chief Justice of India Surya Kant, along with Justices Joymalya Bagchi and N.V. Anjaria.

The company posted its results for the third quarter of FY26 late on Wednesday evening, with its revenue dipping 3% year-on-year to ₹ 2,140 crore, and slipping to a loss of ₹ 136 crore from a net profit of ₹ 4 crore in Q3FY25. Its ebitda margin shrank from 16% in Q3FY25 to 11% this fiscal.

Stocks to Watch: Tata Power received a letter for Jejuri Hinjewadi Power Transmission project. Infosys completed a buyback and saw stake reductions by co-founders' kin. Adani Power is pursuing South Asian projects. Piramal Pharma addressed FDA issues, while Firstsource acquired Pastdue Credit.

Ganesh Dongre of Anand Rathi recommends three stocks to buy on Monday - Indian Energy Exchange, Piramal Pharma Ltd, and Bajaj Finance.

CDMO slowdown dragged Q2FY26 revenues, but Piramal Pharma management expects a rebound in US biopharma funding to boost growth in the next two years.